Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
May 23 2019 - 8:30AM
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company
developing innovative targeted medicines and artificial
intelligence to find, fight and follow cancer, today announced that
four abstracts highlighting AZEDRA (iobenguane I 131) and PyL
(18F-DCFPyL) have been selected for poster presentation at the
upcoming American Society of Clinical Oncology (ASCO) 2019 Annual
Meeting, which will be held from May 31 – June 4, 2019 in Chicago,
Illinois. Details on the presentations are included below.
Date & Time: Saturday June
1, 2019 from 8:00 a.m. to 11:00 a.m. Central TimePoster
Session Title: Developmental Therapeutics and Tumor
Biology (Nonimmuno)Title: A phase II study for
prostate cancer monitoring using 18F-DCFPyL and blood-based
biomarkerAbstract No.: TPS3154Poster Board
No.: 142a
Date & Time: Saturday June
1, 2019 from 1:15 p.m. to 4:15 p.m. Central TimePoster
Session Title: Genitourinary (Prostate)
CancerTitle: Diagnostic performance of 18F-DCFPyL
in the OSPREY Trial: A prospective phase 2/3 multicenter study of
18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected
metastatic prostate cancer (mPC)Abstract No.:
5012Poster Board No.: 124
Date & Time: Saturday June
1, 2019 from 4:30 p.m. to 6:00 p.m. Central TimePoster
Discussion Session Title: Genitourinary (Prostate)
CancerTitle: Diagnostic performance of 18F-DCFPyL
in the OSPREY Trial: A prospective phase 2/3 multicenter study of
18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected
metastatic prostate cancer (mPC)Abstract No.:
5012Poster Board No.: 124
Date & Time: Saturday June
1, 2019 from 1:15 p.m. to 4:15 p.m. Central TimeSession
Title: Developmental Therapeutics and Tumor Biology
(Nonimmuno)Title: A phase III, multicenter study
to assess the diagnostic performance and clinical impact of
18F-DCFPyL PET/CT in men with suspected recurrence of prostate
cancer (CONDOR)Abstract No.: TPS5093Poster
Board No.: 201b
Date & Time: Monday, June
3, 2019 from 8:00 a.m. to 11:00 a.m. Central TimeSession
Title: Gastrointestinal (Noncolorectal)
CancerTitle: Long-term survival and safety from a
multi-center, open-label, pivotal phase 2 study of iobenguane I 131
in patients (Pts) with unresectable, locally advanced or metastatic
pheochromocytoma or paraganglioma (PPGL)Abstract
No.: 4108Poster Board No.: 213
About PROGENICS
Progenics is an oncology company focused on the
development and commercialization of innovative targeted medicines
and artificial intelligence to find, fight and follow cancer,
including: therapeutic agents designed to treat cancer (AZEDRA®,
1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”)
targeted imaging agent for prostate cancer (PyL™); and imaging
analysis technology (aBSI and PSMA AI). Progenics has two
commercial products, AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy; and RELISTOR®
(methylnaltrexone bromide) for the treatment of opioid-induced
constipation, which is partnered with Bausch Health Companies
Inc.
This press release contains projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, market acceptance for approved
products; the risk that the commercial launch of AZEDRA may not
meet revenue and income expectations; the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations; the unpredictability of
the duration and results of regulatory review of New Drug
Applications (NDA) and Investigational NDAs; the inherent
uncertainty of outcomes in the intellectual property disputes such
as the dispute with the University of Heidelberg regarding
PSMA-617; our ability to successfully develop and commercialize
products that incorporate licensed intellectual property; the
effectiveness of the efforts of our partners to market and sell
products on which we collaborate and the royalty revenue generated
thereby; generic and other competition; the possible impairment of,
inability to obtain and costs of obtaining intellectual property
rights; possible product safety or efficacy concerns, general
business, financial, regulatory and accounting matters, litigation
and other risks. More information concerning Progenics and such
risks and uncertainties is available on its website, and in its
press releases and reports it files with the U.S. Securities and
Exchange Commission, including those risk factors included in its
Annual Report on Form 10-K for the year ended December 31, 2018, as
updated in its subsequent Quarterly Reports on Form 10-Q. Progenics
is providing the information in this press release as of its date
and, except as expressly required by law, Progenics disclaims any
intent or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
Contact: Melissa DownsInvestor
Relations(646) 975-2533mdowns@progenics.com
(PGNX-F)
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024